Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (389 views visite)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 1.172, 5-year impact factor Impact factor a 5 anni: 1.202
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77958459740&partnerID=40&md5=69dab00885bf42b303bb2309235ad484
Keywords Parole chiave: 90y, Dota-Peptides, Radiolabelling, Radionuclide Therapy, 90< Sup>y, Critical Factors, Effective Therapy, High Activity, Impact Reaction, Peptide Receptor, Radiochemical Yield, Reaction Conditions, Reaction Temperature, Specific Activity, Statistically Significant Difference, Temperature Constant, Water Baths, Yttrium-90, Association Reactions, Group Technology, High Performance Liquid Chromatography, Quality Control, Radioisotopes, Thin Layer Chromatography, Yttrium Alloys, Reaction Kinetics, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid, Article, Chemical Reaction Kinetics, Controlled Study, Isotope Labeling, Priority Journal, Radioactivity, Radiochemistry, Heterocyclic Compounds, 1-Ring, Humans, Octreotide, Organometallic Compounds, Radiopharmaceuticals, Yttrium Radioisotopes, 1-Ring Chemistry , Isotope Labeling Methods , Octreotide Analogs, Derivatives Chemistry , Organometallic Compounds Chemical Synthesis , Radiopharmaceuticals Chemical Synthesis , Yttrium Radioisotopes Chemistry,
Affiliations Affiliazioni:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche (CNR), Naples, Italy. a.nardelli@libero.it
IRCCS-CROB, Rionero in Vulture, Italy
Dipartimento di Scienze Biomorfologiche e Funzionali, Università Federico II, Via Pansini 5, 80131 Naples, Italy
References Riferimenti:
Breeman, W.A., de Jong, M., Kwekkeboom, D.J., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) Eur. J. Nucl. Med., 28, p. 142
Bunemann, M., Hosey, M.M., G-protein coupled receptor kinases as modulators of G-protein signalling (1999) J. Physiol., 517, p. 5
De Jong, M., Valkema, R., Jamar, F., Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings (2002) Semin Nucl. Med., 32, p. 133
Esser, J.P., Krenning, E.P., Teunissen, J.J., Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 1346
Forrer, F., Uusijärvi, H., Waldherr, C., A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours (2004) Eur. J. Nucl. Med. Mol. Imaging, 31, p. 1257
Kwekkeboom, D., Krenning, E.P., de Jong, M., Peptide receptor imaging and therapy (2000) J. Nucl. Med., 41, p. 1704
Krenning, E.P., Valkema, R., Kooij, P.P., The role of radioactive somatostatin and its analogues in the control of tumor growth (2000) Recent Results Cancer Res., 153, p. 1
Kwekkeboom, D.J., Bakker, W.H., Kooij, P.P., [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients (2001) Eur. J. Nucl. Med., 28, p. 1319
Kukis, D.L., DeNardo, S.J., DeNardo, G.L., Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates (1998) J. Nucl. Med., 39, p. 2105
Liu, S., Cheung, E., Ziegler, M.C., (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy (2001) Bioconjugate Chem., 12, p. 559
Oberg, K., Kvols, L., Caplin, M., Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system (2004) Ann. Oncol., 15, p. 966
Plöckinger, U., Rindi, G., Arnold, R., European Neuroendocrine Tumour Society.Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, p. 394
Wild, D., Schmitt, J.S., Gini, M., DOTANOC, a high-affinity ligand of somatostatin receptors subtypes 2, 3 and 5 for labelling with various radiometals (2003) Eur. J. Nucl. Med., 30, p. 1338
Breeman, W. A., de Jong, M., Kwekkeboom, D. J., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) Eur. J. Nucl. Med., 28, p. 142
Esser, J. P., Krenning, E. P., Teunissen, J. J., Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu-DOTA (0), Tyr (3)] octreotide: which peptide is preferable for PRRT? (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 1346
Forrer, F., Uusij rvi, H., Waldherr, C., A comparison of (111) In-DOTATOC and (111) In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours (2004) Eur. J. Nucl. Med. Mol. Imaging, 31, p. 1257
Krenning, E. P., Valkema, R., Kooij, P. P., The role of radioactive somatostatin and its analogues in the control of tumor growth (2000) Recent Results Cancer Res., 153, p. 1
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients (2001) Eur. J. Nucl. Med., 28, p. 1319
Kukis, D. L., DeNardo, S. J., DeNardo, G. L., Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates (1998) J. Nucl. Med., 39, p. 2105
Pl ckinger, U., Rindi, G., Arnold, R., European Neuroendocrine Tumour Society. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, p. 394
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 1.172, 5-year impact factor Impact factor a 5 anni: 1.202
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-77958459740&partnerID=40&md5=69dab00885bf42b303bb2309235ad484
Keywords Parole chiave: 90y, Dota-Peptides, Radiolabelling, Radionuclide Therapy, 90< Sup>y, Critical Factors, Effective Therapy, High Activity, Impact Reaction, Peptide Receptor, Radiochemical Yield, Reaction Conditions, Reaction Temperature, Specific Activity, Statistically Significant Difference, Temperature Constant, Water Baths, Yttrium-90, Association Reactions, Group Technology, High Performance Liquid Chromatography, Quality Control, Radioisotopes, Thin Layer Chromatography, Yttrium Alloys, Reaction Kinetics, 10 Tetraazacyclododecane 1, 10 Tetraacetic Acid, Article, Chemical Reaction Kinetics, Controlled Study, Isotope Labeling, Priority Journal, Radioactivity, Radiochemistry, Heterocyclic Compounds, 1-Ring, Humans, Octreotide, Organometallic Compounds, Radiopharmaceuticals, Yttrium Radioisotopes, 1-Ring Chemistry , Isotope Labeling Methods , Octreotide Analogs, Derivatives Chemistry , Organometallic Compounds Chemical Synthesis , Radiopharmaceuticals Chemical Synthesis , Yttrium Radioisotopes Chemistry,
Affiliations Affiliazioni:
*** IBB - CNR ***
Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche (CNR), Naples, Italy. a.nardelli@libero.it
IRCCS-CROB, Rionero in Vulture, Italy
Dipartimento di Scienze Biomorfologiche e Funzionali, Università Federico II, Via Pansini 5, 80131 Naples, Italy
References Riferimenti:
Breeman, W.A., de Jong, M., Kwekkeboom, D.J., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) Eur. J. Nucl. Med., 28, p. 142
Bunemann, M., Hosey, M.M., G-protein coupled receptor kinases as modulators of G-protein signalling (1999) J. Physiol., 517, p. 5
De Jong, M., Valkema, R., Jamar, F., Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings (2002) Semin Nucl. Med., 32, p. 133
Esser, J.P., Krenning, E.P., Teunissen, J.J., Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 1346
Forrer, F., Uusijärvi, H., Waldherr, C., A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours (2004) Eur. J. Nucl. Med. Mol. Imaging, 31, p. 1257
Kwekkeboom, D., Krenning, E.P., de Jong, M., Peptide receptor imaging and therapy (2000) J. Nucl. Med., 41, p. 1704
Krenning, E.P., Valkema, R., Kooij, P.P., The role of radioactive somatostatin and its analogues in the control of tumor growth (2000) Recent Results Cancer Res., 153, p. 1
Kwekkeboom, D.J., Bakker, W.H., Kooij, P.P., [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients (2001) Eur. J. Nucl. Med., 28, p. 1319
Kukis, D.L., DeNardo, S.J., DeNardo, G.L., Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates (1998) J. Nucl. Med., 39, p. 2105
Liu, S., Cheung, E., Ziegler, M.C., (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy (2001) Bioconjugate Chem., 12, p. 559
Oberg, K., Kvols, L., Caplin, M., Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system (2004) Ann. Oncol., 15, p. 966
Plöckinger, U., Rindi, G., Arnold, R., European Neuroendocrine Tumour Society.Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, p. 394
Wild, D., Schmitt, J.S., Gini, M., DOTANOC, a high-affinity ligand of somatostatin receptors subtypes 2, 3 and 5 for labelling with various radiometals (2003) Eur. J. Nucl. Med., 30, p. 1338
Breeman, W. A., de Jong, M., Kwekkeboom, D. J., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives (2001) Eur. J. Nucl. Med., 28, p. 142
Esser, J. P., Krenning, E. P., Teunissen, J. J., Comparison of [(177) Lu-DOTA (0), Tyr (3)] octreotate and [(177) Lu-DOTA (0), Tyr (3)] octreotide: which peptide is preferable for PRRT? (2006) Eur. J. Nucl. Med. Mol. Imaging, 33, p. 1346
Forrer, F., Uusij rvi, H., Waldherr, C., A comparison of (111) In-DOTATOC and (111) In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours (2004) Eur. J. Nucl. Med. Mol. Imaging, 31, p. 1257
Krenning, E. P., Valkema, R., Kooij, P. P., The role of radioactive somatostatin and its analogues in the control of tumor growth (2000) Recent Results Cancer Res., 153, p. 1
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo] octreotide in patients (2001) Eur. J. Nucl. Med., 28, p. 1319
Kukis, D. L., DeNardo, S. J., DeNardo, G. L., Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates (1998) J. Nucl. Med., 39, p. 2105
Pl ckinger, U., Rindi, G., Arnold, R., European Neuroendocrine Tumour Society. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) (2004) Neuroendocrinology, 80, p. 394
Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90
Peptide receptor radionuclide therapy (PRRT) has recently expanded due to radiolabelling of DOTA-peptides, such as the somatostatin analogues [DOTA0, Tyr3]octreotate (DOTATATE).The achievement of high specific activities during procedures has been indicated as the critical factor to consent effective therapy. Several radiochemical factors may negatively impact reaction procedures such as pH, temperature and time of reaction. Our study was undertaken to explore the influence of radiochemical parameters, such as time of incubation, on reaction kinetics during the radiolabelling of DOTATATE with 90Y. Methods: Forty-five radiolabelling procedures were carried out using small volumes of yttrium-90, typically 60-78 γL. At nearly constant pH and temperature two different settings of radiolabelling procedures were implemented, removing the products from the heating water bath approximately after 30. min (group E, early; n=20) and after 39. min (group L, later; n=25). Quality controls were performed by means of both high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC). Results: Reaction kinetics for 90Y were found to a provide suitable percentage of incorporation at pH 4.5 for both groups. Reaction temperature was not different between groups E and L. A significant difference was found between the two groups in radiochemical yield, which was 95.6%±0.8 for group E and 98.2%±1.1 for group L (p<0.0001). The specific activity of the final product was 46.9MBq/nmol. Conclusion: In order to achieve optimal specific activities, pH, temperature and time of reaction necessitate careful evaluation and setting. A statistically significant difference in labelling yield was found between a set of procedures completed at 39. min as compared to that executed at 30. min, keep the reaction pH and temperature constant. © 2010 Elsevier Ltd.
Peptide receptor radionuclide therapy (PRRT) has recently expanded due to radiolabelling of DOTA-peptides, such as the somatostatin analogues [DOTA0, Tyr3]octreotate (DOTATATE).The achievement of high specific activities during procedures has been indicated as the critical factor to consent effective therapy. Several radiochemical factors may negatively impact reaction procedures such as pH, temperature and time of reaction. Our study was undertaken to explore the influence of radiochemical parameters, such as time of incubation, on reaction kinetics during the radiolabelling of DOTATATE with 90Y. Methods: Forty-five radiolabelling procedures were carried out using small volumes of yttrium-90, typically 60-78 γL. At nearly constant pH and temperature two different settings of radiolabelling procedures were implemented, removing the products from the heating water bath approximately after 30. min (group E, early; n=20) and after 39. min (group L, later; n=25). Quality controls were performed by means of both high-performance liquid chromatography (HPLC) and thin-layer chromatography (TLC). Results: Reaction kinetics for 90Y were found to a provide suitable percentage of incorporation at pH 4.5 for both groups. Reaction temperature was not different between groups E and L. A significant difference was found between the two groups in radiochemical yield, which was 95.6%±0.8 for group E and 98.2%±1.1 for group L (p<0.0001). The specific activity of the final product was 46.9MBq/nmol. Conclusion: In order to achieve optimal specific activities, pH, temperature and time of reaction necessitate careful evaluation and setting. A statistically significant difference in labelling yield was found between a set of procedures completed at 39. min as compared to that executed at 30. min, keep the reaction pH and temperature constant. © 2010 Elsevier Ltd.
Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90
Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90
Gallicchio R, Scapicchio D, Nardelli A, Pellegrino T, Prisco M, Mainenti P, Sirignano C, Pedicini P, Storto G
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (23 visite) (PDF 2 visite)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
Dettagli Esporta in BibTeX Esporta in EndNote
Caporale A, Bolzati C, Incisivo GM, Salvarese N, Grieco P, Ruvo M
* Improved synthesis on solid phase of dithiocarbamic cRGD-derivative and (99m) Tc-radiolabelling (163 visite)
J Pept Sci (ISSN: 1075-2617linking), 2019 Feb; 25(2): e3140-e3140.
Impact Factor: 1.807
Dettagli Esporta in BibTeX Esporta in EndNote
Caporale A, Bolzati C, M , Incisivo G, Salvarese N, Grieco P, Ruvo M
* Improved synthesis on SPPS of dithiocarbamic cRGD-derivative and its application in 99mTc-radiolabelling (287 visite)
Peptide Science, 2018; N/D: N/D-N/D.
Impact Factor: 1.546
Dettagli Esporta in BibTeX Esporta in EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (337 visite)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (308 visite) (PDF 2 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
Dettagli Esporta in BibTeX Esporta in EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pellegrino T, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of Yttrium-90 (335 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Sep; 36: N/D-N/D.
Impact Factor: 4.531
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (214 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (245 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
Dettagli Esporta in BibTeX Esporta in EndNote
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Gallicchio R, Scapicchio D, Nardelli A, Pellegrino T, Prisco M, Mainenti P, Sirignano C, Pedicini P, Storto G
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (23 visite) (PDF 2 visite)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
Dettagli Esporta in BibTeX Esporta in EndNote
Caporale A, Bolzati C, Incisivo GM, Salvarese N, Grieco P, Ruvo M
* Improved synthesis on solid phase of dithiocarbamic cRGD-derivative and (99m) Tc-radiolabelling (163 visite)
J Pept Sci (ISSN: 1075-2617linking), 2019 Feb; 25(2): e3140-e3140.
Impact Factor: 1.807
Dettagli Esporta in BibTeX Esporta in EndNote
Caporale A, Bolzati C, M , Incisivo G, Salvarese N, Grieco P, Ruvo M
* Improved synthesis on SPPS of dithiocarbamic cRGD-derivative and its application in 99mTc-radiolabelling (287 visite)
Peptide Science, 2018; N/D: N/D-N/D.
Impact Factor: 1.546
Dettagli Esporta in BibTeX Esporta in EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (337 visite)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Gallicchio R, Pellegrino T, Nardelli A, Capacchione D, Sirignano C, Pace L
* Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (308 visite) (PDF 2 visite)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Impact Factor: 2.408
Dettagli Esporta in BibTeX Esporta in EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pellegrino T, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of Yttrium-90 (335 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2009 Sep; 36: N/D-N/D.
Impact Factor: 4.531
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (214 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
Dettagli Esporta in BibTeX Esporta in EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (245 visite)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
Dettagli Esporta in BibTeX Esporta in EndNote
8 Records (4 escludendo Abstract e Conferenze).
Impact factor totale: 23.855 (8.343 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 20.296 (4.221 escludendo Abstract e Conferenze).
Impact factor totale: 23.855 (8.343 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 20.296 (4.221 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:14:59
389 views visite. Last view on Ultima visita in data Sunday 28 March 2021, 8:42:48
ibb.cnr.it